Plasma biomarker analysis of ramucirumab in Japanese patients with advanced gastric cancer.

被引：2
|
作者：
Takahari, Daisuke [1 ]
Wakatsuki, Takeru [1 ]
Mashima, Tetsuo [1 ]
Chin, Keisho [1 ]
Ichimura, Takashi [1 ]
Ogura, Mariko [1 ]
Matsushima, Tomohiro [1 ]
Osumi, Hiroki [1 ]
Nakayama, Izuma [1 ]
Ota, Yumiko [1 ]
Shinozaki, Eiji [1 ]
Suenaga, Mitsukuni [1 ]
Kawata, Naomi [1 ]
Horiike, Yuki [1 ]
Seimiya, Hiroyuki [1 ]
Fujita, Naoya [1 ]
Yamaguchi, Kensei [1 ]
机构：
[1] Japanese Fdn Canc Res, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.81
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
81
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Capecitabine and docetaxel for advanced gastric cancer.
    Thuss-Patience, P. C.
    Kretzschmar, A.
    Dogan, Y.
    Blau, I.
    Pink, D.
    Lebedinzew, B.
    Micheel, S.
    Dörken, B.
    Reichardt, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 195S - 195S
  • [32] Chemoradiotherapy for highly advanced gastric cancer.
    Tsutsui, Mai
    Takahashi, Tsunehiro
    Saikawa, Yoshiro
    Kawakubo, Hirofumi
    Wada, Norihito
    Takeuchi, Hiroya
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [33] Prognostic biomarker in advanced gastric cancer
    Mi, Lan
    Ji, Xin
    Ji, Jiafu
    TRANSLATIONAL GASTROINTESTINAL CANCER, 2016, 5 (01) : 16 - 29
  • [34] Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients
    Jinchul Kim
    Seonggyu Byeon
    Hyera Kim
    Ja Hyun Yeo
    Jung Yong Hong
    Jeeyun Lee
    Ho Yeong Lim
    Won Ki Kang
    Seung Tae Kim
    Targeted Oncology, 2020, 15 : 203 - 209
  • [35] A phase II study of trifluridine/tipiracil and ramucirumab in patients with unresectable advanced or recurrent gastric cancer
    Ando, T.
    Kawazoe, A.
    Hosaka, H.
    Fujita, J.
    Koeda, K.
    Nishikawa, K.
    Amagai, K.
    Fujitani, K.
    Ogata, K.
    Yamamoto, Y.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1290 - S1290
  • [36] Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients
    Kim, Jinchul
    Byeon, Seonggyu
    Kim, Hyera
    Yeo, Ja Hyun
    Hong, Jung Yong
    Lee, Jeeyun
    Lim, Ho Yeong
    Kang, Won Ki
    Kim, Seung Tae
    TARGETED ONCOLOGY, 2020, 15 (02) : 203 - 209
  • [37] A phase II biomarker-oriented study to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer.
    Kim, Tae-Yong
    Yoon, Jeesun
    Lee, Dae-Won
    Im, Seock-Ah
    Nam, Ah-Rong
    Bang, Ju-Hee
    Oh, Kyoung-Seok
    Kim, Jae-Min
    Jeong, Yoojin
    Choo, Sea Young
    Kim, Hyo Jung
    Lee, Su In
    Oh, Do-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 404 - 404
  • [38] Phase 1b study of first-line Ramucirumab plus Platinum plus Fluoropyrimidine in Japanese Patients with advanced gastric cancer
    Kadowaki, Shigenori
    Shitara, Kohei
    Sakai, Daisuke
    Nishina, Tomohiro
    Yoshikawa, Reigetsu
    Piao, Yongzhe
    Ozeki, Akichika
    Inoue, Koichi
    Muro, Kei
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] Adjuvant chemotherapy in gastric cancer. Japanese approach
    Nakajima, T
    PROGRESS IN GASTRIC CANCER RESEARCH 1997: PROCEEDINGS OF THE 2ND INTERNATIONAL GASTRIC CANCER CONGRESS, 1997, : 1451 - 1456
  • [40] Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma
    Young, Kate
    Smyth, Elizabeth
    Chau, Ian
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2015, 8 (06) : 373 - 383
12345